Last checked at 
(Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has selected US-based AGC Biologics as the commercial manufacturer for Faron's Clevegen cancer therapy.
The clinical stage biopharmaceutical company hailed AGC's "regulatory knowledge on commercial scale production".
Faron said: "The commercial scale manufacturing process established by AGC Biologics will also provide a dossier to support future regulatory filings in Europe and the US.
"Biologics has decades of experience in manufacturing of biotechnological products, including commercial market supplies of US Food & Drug Administration, Product Development & Management Association and European Medicines Agency approved products."
Faron shares were 2.8% higher at 370.00 pence each in London on Tuesday afternoon.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
